A formulation of rituximab administered by subcutaneous injection appears to be just as safe and effective in the treatment of follicular lymphoma as IV rituximab, according to a Phase III multinational trial.
Use of the subcutaneous agent, which contains the same monoclonal antibody as the IV version, could significantly reduce the amount of time patients spend in treatment visits.
“This study does give us a potential new option for these patients,” said Craig A. Portell, MD, an